Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Third Wave Tumble 5.9 Percent

This article incorrectly reported that Piper Jaffray downgraded Third Wave's shares today. In fact, Piper downgraded the stock on March 1, not April 1.

NEW YORK, April 1 (GenomeWeb News) - Shares in Third Wave Technoloigies were down 5.9 percent, or $.34, at $5.42 in mid-afternoon trading.

 

As GenomeWeb News  reported, Third Wave in February reported a 16.5-percent drop in fourth-quarter revenue and almost tripled losses for the fourth quarter of 2004.

 

The company had $8.1 million in revenues, down from $9.7 million during the same quarter in 2003. Third Wave said that more than half, or $4.7 million, of total revenues were derived from clinical molecular diagnostics, meaning that this business segment grew almost 90 percent compared to the fourth quarter of 2003.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.